Abstract
In recent years, significant efforts have been made on studying and engineering adeno-associated virus (AAV) capsid, in order to increase efficiency in targeting specific cell types that are non-permissive to wild type (wt) viruses and to improve efficacy in infecting only the cell type of interest. With our previous knowledge of the viral properties of the naturally occurring serotypes and the elucidation of their capsid structures, we can now generate capsid mutants, or hybrid serotypes, by various methods and strategies. In this review, we summarize the studies performed on AAV retargeting, and categorize the available hybrid serotypes to date, based on the type of modification: 1) transcapsidation, 2) adsorption of bi-specific antibody to capsid surface, 3) mosaic capsid, and 4) chimeric capsid. Not only these hybrid serotypes could achieve high efficiency of gene delivery to a specific targeted cell type, which can be better-tailored for a particular clinical application, but also serve as a tool for studying AAV biology such as receptor binding, trafficking and genome delivery into the nucleus.
Keywords: adeno associated virus, serotypes, capsids, tissue tropism
Current Gene Therapy
Title: AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Volume: 5 Issue: 3
Author(s): Vivian W. Choi, Douglas M. McCarty and R. Jude Samulski
Affiliation:
Keywords: adeno associated virus, serotypes, capsids, tissue tropism
Abstract: In recent years, significant efforts have been made on studying and engineering adeno-associated virus (AAV) capsid, in order to increase efficiency in targeting specific cell types that are non-permissive to wild type (wt) viruses and to improve efficacy in infecting only the cell type of interest. With our previous knowledge of the viral properties of the naturally occurring serotypes and the elucidation of their capsid structures, we can now generate capsid mutants, or hybrid serotypes, by various methods and strategies. In this review, we summarize the studies performed on AAV retargeting, and categorize the available hybrid serotypes to date, based on the type of modification: 1) transcapsidation, 2) adsorption of bi-specific antibody to capsid surface, 3) mosaic capsid, and 4) chimeric capsid. Not only these hybrid serotypes could achieve high efficiency of gene delivery to a specific targeted cell type, which can be better-tailored for a particular clinical application, but also serve as a tool for studying AAV biology such as receptor binding, trafficking and genome delivery into the nucleus.
Export Options
About this article
Cite this article as:
Choi W. Vivian, McCarty M. Douglas and Samulski Jude R., AAV Hybrid Serotypes: Improved Vectors for Gene Delivery, Current Gene Therapy 2005; 5 (3) . https://dx.doi.org/10.2174/1566523054064968
DOI https://dx.doi.org/10.2174/1566523054064968 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Hedgehog Pathway: The development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway
Mini-Reviews in Medicinal Chemistry Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Photodynamic Therapy: The Development of New Photosensitisers
Anti-Cancer Agents in Medicinal Chemistry The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma
Current Pharmaceutical Design Self-Adjuvanting Lipopeptide Vaccines
Current Medicinal Chemistry Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Current Medicinal Chemistry The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry Amino Acid Derived Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Specificity of Binding in Protein Kinases
Current Enzyme Inhibition On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Look Into My Onco-forest - Review of Plant Natural Products with Anticancer Activity
Current Topics in Medicinal Chemistry P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design